Author: RR

FDA Approves ZYNYZ® for Squamous Cell Carcinoma of the Anal Canal

RR

SUMMARY: The FDA on May 15, approved Retifanlimab-dlwr (ZYNYZ®), a PD-1–blocking monoclonal antibody, with Carboplatin and Paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic Squamous Cell carcinoma of the Anal Canal (SCAC). The FDA also approved Retifanlimab as a single agent for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.

The American Cancer Society estimates that 10,930 new cases of Anus, anal canal, and anorectum cancers will be diagnosed in 2025, and 2030 individuals will die of the disease. Squamous Cell carcinoma of the Anal Canal (SCAC) is a rare but increasingly prevalent malignancy, closely associated with persistent infection by high-risk Human PapillomaVirus (HPV), particularly HPV-16 and HPV-18. HPV-driven oncogenesis plays a pivotal role in SCAC development by disrupting tumor suppressor proteins such as p53 and Rb via viral oncoproteins E6 and E7. These oncoproteins also generate a highly immunogenic Tumor MicroEnvironment (TME), recruiting Tumor-Infiltrating Lymphocytes (TILs) and expressing immune checkpoints like PD-L1, providing a compelling rationale for the use of Immune Checkpoint Inhibitors (ICIs) in this disease.

While early-stage SCAC is often curable with chemoradiation, outcomes in advanced or metastatic cases remain poor, with 5-year survival dropping to 30% in Stage IV disease. Platinum-based chemotherapy, particularly the combination of Carboplatin and Paclitaxel as established by the InterAAct trial, has been the frontline standard. However, outcomes have remained suboptimal, fueling efforts to explore combination regimens that leverage the immunogenicity of HPV-driven SCAC.

Rationale for Immunotherapy in SCAC

HPV-positive tumors are characterized by an “inflamed” TME, enriched with TILs and immune regulatory molecules such as PD-1 and PD-L1. This immune signature is associated with both favorable prognosis and responsiveness to immunotherapy. ICIs like Pembrolizumab and Nivolumab have demonstrated modest activity as monotherapy in pretreated SCAC, with Overall Response Rates (ORR) ranging from 13% to 30% and median Progression-Free Survival (PFS) of approximately 2-4 months. However, these agents alone have not transformed outcomes, prompting exploration of synergistic strategies.

Preclinical studies indicate that chemotherapy can enhance immunogenic cell death, promote antigen presentation, and reduce immunosuppressive myeloid populations, thus priming the TME for immune-based therapies. These insights provided the foundation for evaluating the anti–PD-1 antibody Retifanlimab in combination with Carboplatin and Paclitaxel.

Retifanlimab (ZYNYZ®) is a humanized monoclonal antibody targeting PD-1, thereby restoring T-cell activity against tumor cells.

POD1UM-303 (InterAACT 2; NCT04472429) was a randomized, double-blind, multicenter Phase 3 trial that enrolled 308 patients across 81 centers with inoperable, locally recurrent, or metastatic SCAC who were chemotherapy-naive in the advanced setting. Participants received standard Carboplatin (AUC 5, IV day 1) and Paclitaxel (80 mg/m² IV, days 1, 8, and 15) for six cycles, and were randomized 1:1 to receive either:

  • Retifanlimab 500 mg IV every 4 weeks, or
  • Placebo IV every 4 weeks
    Treatment was continued for up to one year or until disease progression or unacceptable toxicity. Cross-over to single-agent Retifanlimab was allowed for patients in the placebo arm upon disease progression.

The Primary endpoint was Progression-Free Survival (PFS) per RECIST v1.1 by Blinded Independent Central Review. Key Secondary endpoints included Overall Survival (OS), Overall Response Rate (ORR), and Duration of Response (DoR).

Clinical Outcomes

  • Progression-Free Survival:
    • Retifanlimab arm: 9.3 months (95% CI, 7.5–11.3)
    • Placebo arm: 7.4 months (95% CI, 7.1–7.7)
    • Hazard ratio: 0.63 (95% CI, 0.47–0.84; P=0.0006)
  • Overall Survival (Interim Analysis):
    • Retifanlimab arm: 29.2 months (95% CI, 24.2–NE)
    • Placebo arm: 23.0 months (95% CI, 15.1–27.9)
    • HR: 0.70 (95% CI, 0.49–1.01), not yet statistically significant
  • Overall Response Rate:
    • Retifanlimab arm: 56% (95% CI, 48%–64%)
    • Placebo arm: 44% (95% CI, 36%–52%)
  • Disease Control Rate: 87% vs 80%, respectively
  • Crossover Allowed: 45% of patients in the placebo arm received Retifanlimab upon progression.

Safety and Tolerability

The combination of Retifanlimab and chemotherapy was generally well tolerated. Immune-related Adverse Events (AEs) increased, as expected with PD-1 blockade, but were manageable and did not significantly impact chemotherapy delivery or dose intensity.

Monotherapy Insights: POD1UM-202

Retifanlimab was also studied as a single agent in POD1UM-202 (NCT03597295), a Phase 2 trial of 94 patients with previously treated, platinum-refractory SCAC:

  • ORR: 14% (95% CI, 8%–23%)
  • Median DOR: 9.5 months
  • Notable Findings: Better responses observed in p16-positive and PD-L1–positive tumors; tumor inflammation signature scores correlated with improved survival.

Conclusion and Clinical Implications

The POD1UM-303 trial marks a major advancement in the treatment of advanced SCAC. Retifanlimab in combination with Carboplatin and Paclitaxel not only met its Primary endpoint but also demonstrated consistent improvements in response rates, survival outcomes, and disease control, without compromising safety.

As the first positive Phase 3 study in this setting, POD1UM-303 establishes a new standard of care for patients with advanced SCAC and solidifies the role of immunotherapy in HPV-associated malignancies. Continued exploration of predictive biomarkers and deeper understanding of the TME will be critical to refining treatment strategies in this rare but challenging cancer.

POD1UM-303/InterAACT 2: Phase 3 study of retifanlimab with carboplatin-paclitaxel (C-P) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo). Rao S, et al. ESMO Congress 2024, LBA2

Pregnancy-Specific Glycoproteins Linked to Poorer Prognosis in Female Lung Adenocarcinoma Patients

RR

SUMMARY: Pregnancy-Specific Glycoproteins (PSGs), traditionally known for their role in fetal development and maternal immune tolerance, are emerging as unexpected contributors to oncologic processes. These placental proteins, members of the CarcinoEmbryonic Antigen Cell Adhesion Molecule (CEACAM) family and the broader immunoglobulin superfamily, are produced by trophoblasts and secreted into maternal circulation during pregnancy in high concentrations and act as immunomodulators, facilitating maternal-fetal tolerance and vascular remodeling. However, recent evidence suggests that these proteins may be aberrantly expressed in several malignancies, including lung cancer, with potentially detrimental effects, particularly among female patients.

Background and Rationale
While PSGs are primarily restricted to the placenta under normal physiological conditions, prior research has revealed their ectopic expression in various cancers such as breast, ovarian, uterine, and colon tumors. Their expression in these settings has been correlated with poorer overall survival. Yet the mechanisms and potential sex-specific effects remained unclear. Recognizing the immunological parallels between pregnancy and tumor immune evasion, researchers hypothesized that PSGs might confer a selective disadvantage in cancers by modulating the tumor microenvironment in a sex-dependent manner.

Study Design and Methodology
To explore this hypothesis, investigators conducted a sex-stratified analysis of PSG expression and survival outcomes using two independent transcriptomic datasets: The Cancer Genome Atlas (TCGA), encompassing 235 male and 271 female Lung Adenocarcinoma patients, and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), including 70 male and 36 female patients. PSG mRNA expression profiles were integrated into machine learning models to assess their prognostic value. Key PSG family members, PSG3, PSG7, and PSG8 were specifically examined for their association with survival outcomes.

Key Findings
This analysis revealed a striking sex-specific prognostic disparity in Lung Adenocarcinoma. Female patients with elevated PSG expression exhibited significantly worse Overall Survival compared to their PSG-negative counterparts, a trend not observed in male patients. Notably, a combined expression signature of PSG3, PSG7, and PSG8 identified a high-risk subgroup encompassing approximately 30% of female patients. This signature was significantly associated with poor prognosis.

Pathway enrichment analysis further uncovered that PSG-expressing female Lung Adenocarcinoma tumors showed upregulation of the “KRAS Signaling Down” pathway, suggesting a potential mechanistic link. Incorporating KRAS pathway activity into the predictive model improved its prognostic performance in female patients, reinforcing the notion that PSGs may interface with oncogenic KRAS signaling in a sex-dependent fashion.

Clinical Implications
These findings underscore a previously unrecognized, sex-specific role for PSGs in modulating lung cancer outcomes. The ectopic expression of PSGs appears to mimic their immune-regulatory function during pregnancy, potentially allowing tumors to evade immune surveillance, particularly in female patients. As a result, PSG expression may serve as a prognostic biomarker and a novel therapeutic target in Lung Adenocarcinoma.

The research team is now investigating the development of antibody-based therapeutics aimed at inhibiting PSG expression, with the goal of improving outcomes in this vulnerable subgroup of female Lung Adenocarcinoma patients. Given that PSGs are typically silenced outside of pregnancy, targeting them may provide a tumor-specific strategy with minimal off-target effects.

Future Directions
Further investigations are planned to delineate the interplay between PSG expression, pregnancy history, and hormone-related gene activity. Such studies could elucidate whether reproductive history or endocrine factors influence the reactivation of PSG genes in female tumors, potentially refining risk stratification and therapeutic approaches.

Conclusion
This research highlights the adaptive reuse of fetal tolerance mechanisms by tumors and reveals PSGs as key contributors to sex-specific disparities in Lung Adenocarcinoma prognosis. By integrating transcriptomic profiling with clinical outcomes and pathway analysis, this study provides a compelling rationale for the clinical development of PSG-targeted therapies in female Lung Adenocarcinoma.

Pregnancy-specific glycoproteins in tumors are strong predictors of outcome in female lung adenocarcinoma patients. Oh JH, Rizzuto G, Elkin R, et al. Presented on April 28, 2025: AACR Annual Meeting 2025.

Rising Incidence of Pancreatic and Colorectal Adenocarcinoma among Younger Populations

RR

SUMMARY: The American Cancer Society estimates that in 2025, about 67,440 people will be diagnosed with pancreatic cancer and 51,980 people will die of the disease. Detecting cancer at early stages can significantly increase survival rates and outcomes. Pancreatic Ductal AdenoCarcinoma (PDAC) is one of the most lethal malignancies, ranking among the leading causes of cancer-related mortality globally. A significant challenge in improving PDAC outcomes is its frequent diagnosis at an advanced stage, when therapeutic options are limited and prognosis is poor, with a 5-year survival rate of approximately 10%. Early detection is critical to expanding treatment possibilities and enhancing survival rates. Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society estimates that approximately 154,270 new cases of CRC will be diagnosed in the United States in 2025 and about 52,900 patients will die of the disease. Even though the diagnosis of colorectal cancer in the US is dropping among people 65 years and older, the incidence has been rising in the younger age groups, with 12% of colorectal cancer cases diagnosed in people under age 50, leading to revisions in screening guidelines.

Study Objective
To provide an updated analysis of Annual Percentage Changes (APCs) in the incidence of pancreatic and colorectal adenocarcinoma across different age groups, focusing on younger populations, using data from the SEER database (2000–2021).

Methods
Data Source

  • SEER (Surveillance, Epidemiology, and End Results) database (22 registries, ~47.9% of US population)
  • Data updated through April 17, 2024

Study Design

  • Retrospective cohort study
  • Inclusion: Pancreatic and colorectal adenocarcinoma only
  • Exclusion: Rare pancreatic cancer subtypes (e.g., neuroendocrine tumors, mucinous cystadenocarcinoma)
  • The Rutgers University IRB exempted the study, and informed consent was not needed owing to the deidentified nature of the data.

Analysis

  • Yearly incidence rates per 100,000 population
  • Annual Percentage Changes (APCs) and 95% confidence intervals calculated for three age groups:
    • 15–34 years
    • 35–54 years
    • 55+ years

Results
Pancreatic Adenocarcinoma

  • Total cases (2000–2021): 275,273
    • 51.8% male, 87.1% aged ≥55 years
  • APC in 15–34 years: 4.35% (95% CI, 2.03–6.73)
  • APC in 35–54 years: 1.54% (95% CI, 1.18–1.90)
  • APC in 55+ years: 1.74% (95% CI, 1.59–1.89)

The APC for pancreatic adenocarcinoma in the group aged 15 to 34 year was statistically significantly higher than the APCs of 1.74 (P =0.007) for the group aged 55 years and older and 1.54 (P =0.004) for the group aged 35 to 54 years. The authors commented that the dramatic increase in the APC in the younger population suggests that close attention should be paid to this trend.

Colorectal Adenocarcinoma

  • Total cases: 1,215,200
    • 52.8% male, 80.4% aged ≥55 years
  • APC in 15–34 years: 1.75% (95% CI, 1.08–2.42)
  • APC in 35–54 years: 0.78% (95% CI, 0.51–1.06)
  • APC in 55+ years: -3.31% (95% CI, -3.54 to -3.08)

The APC for colorectal adenocarcinoma for the group aged 55 years and older was statistically significantly lower than the APCs for the group aged 15 to 34 years (P =0.001) and for the group aged 35 to 54 years (P =0.002). Most declines in colorectal cancer incidence was attributed to increased screening in older adults. Screening age was lowered from 50 to 45 years and may likely reduce future incidence in those aged 35–54.

Interpretation & Implications

Pancreatic Cancer

  • Though rare, pancreatic adenocarcinoma in young adults (15–34 years) is rising at an alarming rate.
  • Potential contributors: Smoking, alcohol, environmental exposures, though definitive causes remain unclear.
  • Clinician awareness is critical when evaluating younger patients with:
    • Abdominal pain
    • Weight loss
    • Anemia
    • Family history of pancreatic cancer

Clinical Insight: Historically, the above findings are not investigated in a young individual. It is therefore important to make sure a serious condition is not missed.

Colorectal Cancer

  • Increasing in younger groups, despite an overall declining trend.
  • This supports recent screening age revisions and highlights the need for vigilance in symptomatic young patients.

Limitations

  • SEER data covers ~47.9% of the U.S. population.
  • However, SEER is designed for accurate trend analysis and has reliable coding for common cancers like pancreatic and colorectal adenocarcinoma.
  • Restricting to adenocarcinoma improves the homogeneity and accuracy of the study.

Conclusions

  • Pancreatic adenocarcinoma incidence is rising in all age groups, especially in the youngest cohort (15–34 years).
  • Colorectal adenocarcinoma is increasing among younger individuals, while declining among those 55 and older.
  • Clinicians must heighten awareness of these trends and consider appropriate workups in symptomatic younger patients.

Key Takeaways

  • Pancreatic adenocarcinoma incidence rose >4% annually in individuals aged 15–34 years.
  • Colorectal adenocarcinoma also increased among patients aged 15–34 years.
  • Consider early imaging and endoscopic evaluations in symptomatic young adults.
  • Continue to support early screening efforts, especially for high-risk individuals.

Incidence of Pancreas and Colorectal Adenocarcinoma in the US. Bussetty A, Shen J, Benias PC, et al. JAMA Netw Open. 2025;8(4):e254682. doi:10.1001/jamanetworkopen.2025.4682

 

 

 

 

 

Underutilization of Treatment Intensification in mCSPC: Persistent Gaps between Guidelines and Practice

RR

SUMMARY: Prostate cancer is the most common cancer in American men with the exclusion of skin cancer, and 1 in 8 men will be diagnosed with prostate cancer during their lifetime. The American Cancer Society estimates that in the United States, about 313,780 new cases of prostate cancer will be diagnosed in 2025 and 35,770 men will die of the disease.

The development and progression of prostate cancer is driven by androgens. Androgen Deprivation Therapy (ADT) or testosterone suppression has therefore been the cornerstone of treatment of advanced prostate cancer, and is the first treatment intervention. Androgen Deprivation Therapies have included bilateral orchiectomy or Gonadotropin Releasing Hormone (GnRH) analogues, with or without first generation Androgen Receptor (AR) inhibitors such as CASODEX® (Bicalutamide), NILANDRON® (Nilutamide) and EULEXIN® (Flutamide), or with second generation Androgen Receptor Pathway Inhibitors (ARPIs), which include ZYTIGA® (Abiraterone), XTANDI® (Enzalutamide), ERLEADA® (Apalutamide) and NUBEQA® (Darolutamide). Approximately 10-20% of patients with advanced prostate cancer will progress to Castration Resistant Prostate Cancer (CRPC) within five years during ADT, and over 80% of these patients will have metastatic disease at the time of CRPC diagnosis.

Evidence from clinical trials indicates treatment intensification by combining ADT with ARPIs like Enzalutamide, Apalutamide, Abiraterone, or Darolutamide/chemotherapy, enhances survival in individuals with metastatic Castration-Sensitive Prostate Cancer (mCSPC). Despite clear, consensus-driven guidelines recommending treatment intensification (TI) for mCSPC, real-world data consistently show that many patients are not receiving evidence-based first-line combination therapy. This ongoing implementation gap could have significant consequences for patient survival and reflects a complex interplay of clinical, cognitive, and systemic factors.

Clinical Rationale for Treatment Intensification
Treatment Intensification, defined as the addition of an ARPI such as Abiraterone, Enzalutamide, Apalutamide, or Darolutamide, and/or Docetaxel chemotherapy to Androgen Deprivation Therapy (ADT), is supported by robust evidence from multiple Phase 3 clinical trials. These trials have demonstrated consistent Overall Survival (OS) benefits across broad patient populations with mCSPC. Median OS has improved from under three years in the pre-Treatment Intensification era to 50–60 months with modern combination approaches. As a result, major guidelines including NCCN, ASCO, and the American Urological Association now uniformly endorse Treatment Intensification as the standard of care for men with mCSPC who can tolerate it.

Real-World Underutilization of Treatment Intensification (TI)
Nevertheless, studies repeatedly show that Treatment Intensification remains underutilized in clinical practice. A recent analysis of 617 US patients with mCSPC, derived from the Adelphi Real World (ARW) of 107 US-based physicians, spanning July 2018 to January 2022, found that 69.7% of patients did not receive Treatment Intensification as initial therapy. Notably, this underuse persisted despite the availability of FDA-approved therapies and updates to treatment guidelines during this timeframe.

Similar trends have been observed in claims-based studies and physician-reported treatment patterns. A 2020 global survey revealed that 47% of patients worldwide and 36% in the U.S. did not receive Treatment Intensification. Concerningly, physician rationales often involved misinterpretations of the guidelines or concerns about treatment-related toxicity, even though trials have shown that Treatment Intensification maintains, and in some cases improves Quality of Life (QoL).

Key Findings from the ARW Survey
Physicians participating in the ARW study included medical oncologists (60.7%) and urologists (39.3%), mostly practicing in community settings. Of the 617 patients, 24.8% were African American, 8.1% were Hispanic or Latino, 58.0% were White or Caucasian, and 9.1% were of other race or ethnicity. Of note:

  • Tolerability and Guidelines were top-cited reasons for both prescribing and omitting Treatment Intensification (TI).
    • 64.7% of those prescribing TI cited favorable tolerability.
    • 58.6% of those avoiding TI cited tolerability concerns.
    • Similarly, guideline adherence was cited by 61.5% of TI users and 53.5% of non-TI users, revealing considerable guideline misinterpretation.
  • Disease burden influenced TI use. Patients with higher PSA levels, Gleason grade, and high-volume disease were more likely to receive TI. For instance:
    • PSA ≥75% reduction goals were associated with increased TI use (OR = 1.63).
    • High PSA levels were a driver for 39% of TI prescribers vs. 18.4% of non-TI prescribers (P < .001).
  • Guideline awareness was a significant predictor. Physicians who explicitly cited guidelines were more than three times as likely to prescribe TI (OR = 3.46; P = .01).
  • Misconceptions persist. Among patients who did not receive ARPIs, 31.4% of physicians cited a lack of perceived clinical trial evidence supporting survival benefits, despite level-one data to the contrary.
  • PSA targets may be misaligned. Many physicians aim for a 50% PSA reduction or PSA levels around 2.0 ng/mL, far above the <0.2 ng/mL level retrospectively linked to better outcomes. This disconnect may influence decision-making and undervalue the full benefits of TI.
  • Treatment access and Reimbursement. The physicians reported that only 4.9% of patients were not prescribed the treatment due to insurance coverage limitations. This suggests that access to the treatment, based on insurance, is not a major barrier to treatment.

Barriers beyond Clinical Characteristics
Contrary to initial hypotheses, access and reimbursement were infrequently cited as barriers. Only 4.9% of physicians indicated that insurance coverage prevented Treatment Intensification use. Furthermore, treatment decisions were rarely driven by patient preferences or behavior. Instead, the dominant theme is knowledge gaps in guideline familiarity, evidence interpretation, and understanding of Treatment Intensification’s impact on QoL and toxicity. Many physicians appear to base decisions on outdated assumptions or incomplete reading of the literature.

Toward Better Implementation: The Role of Education
Researchers argue that continued education for both clinicians and patients is essential. Oncologists often treat multiple malignancies and may struggle to stay current. Urologists, who balance surgical and medical roles, face similar constraints. Accessible continuing medical education (CME) programs and direct patient education may help address this disconnect.

Encouragingly, recent data from the Flatiron Health EHR database suggest progress. As of early 2025, 76.8% of patients treated in large academic and community oncology centers were receiving Treatment Intensification. However, questions remain about uptake in smaller or more rural practices.

Conclusion and Call to Action
This study reinforces the importance of bridging the gap between evidence and practice. Although Treatment Intensification in mCSPC is backed by compelling evidence and endorsed by all major guidelines, many patients continue to receive suboptimal therapy due to misconceptions and outdated practice patterns.

Key takeaways for clinicians:

  • Treatment Intensification is the standard of care in eligible patients with mCSPC, across disease volumes and PSA levels.
  • Clinical trials consistently show Treatment Intensification improves OS without compromising QoL.
  • Misinterpretation of guidelines and concerns over tolerability remain major barriers.
  • Improved education and dissemination of trial data are critical to closing the gap.

Addressing these issues is essential to ensure all patients with mCSPC receive life-prolonging therapies in line with current evidence and best practice.

Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer. Agarwal N, George DJ, Klaassen Z, et al. JAMA Netw Open. 2024;7(12):e2448707. doi:10.1001/jamanetworkopen.2024.48707

 

Zongertinib Shows Promising Efficacy and Safety in HER2-Mutant NSCLC: Insights from the Beamion LUNG-1 Trial

RR

SUMMARY: The American Cancer Society estimates that for 2025, about 226,650 new cases of lung cancer will be diagnosed and 124,730 patients will die of the disease. Lung cancer is the leading cause of cancer-related mortality in the United States. Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancers and Adenocarcinoma is now the most frequent histologic subtype of lung cancer.

The HER or erbB family of receptors consist of HER1, HER2, HER3 and HER4. HER2 is a Tyrosine Kinase Receptor expressed on the surface of several tumor types including Breast, Gastric, Lung and Colorectal cancers. It is a growth-promoting protein, and HER2 overexpression/HER2 gene amplification is often associated with aggressive disease and poor prognosis in certain tumor types.

HER2 mutations unlike HER2 overexpression and gene amplification are oncogenic drivers and are detected in 2 to 4% of NSCLCs. They are more often detected in younger, female and never-smokers, and almost exclusively in Adenocarcinomas. Next-generation sequencing is used to identify HER2 mutations. Majority of HER2 mutations (80-90%) occur in exon 20, as either a duplication or an insertion of 12 nucleotides, resulting in the addition of four amino acids (YVMA) at codon 775 in the kinase domain. This distinct molecular entity is characterized by specific pathological and clinical behavior. These acquired HER2 gene mutations have been independently associated with cancer cell growth, aggressive form of disease and poor prognosis, and with an increased incidence of brain metastases.

The FDA in 2022 granted accelerated approval to ENHERTU&reg; (Trastuzumab deruxtecan), for adult patients with unresectable or metastatic NSCLC whose tumors have HER2 (ERBB2) mutations. This is the first drug approved for HER2-mutant NSCLC. Trastuzumab deruxtecan however can be associated with toxicities including Interstitial Lung Disease (ILD). Similarly, pan-HER TKIs such as Poziotinib and Pyrotinib have shown limited efficacy and are frequently associated with EGFR-related adverse events, underscoring the urgent need for more targeted, better-tolerated therapies.

Zongertinib is a novel, oral, irreversible Tyrosine Kinase Inhibitor designed to selectively target HER2 while sparing EGFR, thus minimizing common toxicities such as rash and diarrhea.

Beamion LUNG-1 is an ongoing Phase 1a/1b trial evaluating Zongertinib in previously treated patients with HER2-altered advanced or metastatic solid tumors (Phase 1a) and those with HER2-mutant advanced or metastatic NSCLC across multiple clinically relevant patient cohorts (Phase 1b). In the Phase 1a dose-escalation trial, Zongertinib showed encouraging preliminary activity at the recommended expansion doses of 120 mg and 240 mg once daily, with a low incidence of Grade 3 or higher adverse events.

The Phase 1b portion of the study evaluated Zongertinib in three key populations:

  • Cohort 1: Patients with tumors harboring HER2 mutations in the TKD (Tyrosine Kinase Domain), the most common category of HER2 mutations encountered in the clinic.
  • Cohort 5: Patients whose tumors had HER2 mutations within the TKD and had previously received HER2-directed ADCs, including Trastuzumab deruxtecan.
  • Cohort 3: Patients whose tumor had HER2 mutations outside the TKD.

Patients were initially treated at 120 mg or 240 mg daily and following interim analysis, 120 mg was selected as the optimal dose based on a favorable efficacy and safety balance. The median age in Cohort 1 was 62 yrs. The Primary end point was an Objective Response Rate (ORR) assessed by Blinded Independent Central Review (Cohorts 1 and 5) or by Investigator Review (Cohort 3). Secondary end points included the Duration of Response and Progression-Free Survival (PFS).

Efficacy Outcomes
The median follow-up was 11.3 months at the data-cutoff date. Zongertinib demonstrated robust and durable activity, particularly in Cohort 1:

  • Cohort 1 (N=75 at 120 mg daily dose):
    • Objective response rate (ORR): 71% (P<0.001)
    • Median Duration of Response (DoR): 14.1 months
    • Median progression-free survival (PFS): 12.4 months

Importantly, responses were consistent across subgroups, including patients with brain metastases (ORR: 64%) and common TKD insertion subtypes such as A775_G776insYVMA (ORR: 81%).

  • Cohort 5 (N=31):
    • ORR: 48%, including patients previously treated with Trastuzumab deruxtecan (ORR: 42%)
  • Cohort 3 (N=20):
    • ORR: 30%
    • Activity observed across several non-TKD mutations (e.g., S310X, V659E)

These findings suggest that Zongertinib may offer a viable treatment option even in patients who have progressed on ADCs or harbor atypical HER2 alterations.

Safety and Tolerability
Zongertinib was well tolerated across all cohorts:

  • Grade ≥3 drug-related adverse events occurred in:
    • 17% of patients in Cohort 1
    • 3% in Cohort 5
    • 25% in Cohort 3
  • No cases of drug-related interstitial lung disease were observed
  • Most common adverse event was diarrhea (any grade: 56%; grade ≥3: 1%), followed by rash (all grade ≤2)

The safety profile compares favorably with existing HER2-targeted agents, including Trastuzumab deruxtecan, which has reported interstitial lung disease rates of up to 26% in earlier trials.

Clinical Context and Future Directions
Compared with other HER2-targeted agents including Trastuzumab deruxtecan and investigational pan-HER TKIs, Zongertinib stands out for its high response rates, durability, and manageable toxicity. While cross-study comparisons have inherent limitations, these results support Zongertinib as a promising, HER2-selective oral agent for patients with HER2-mutant NSCLC. The ongoing Phase 3 Beamion LUNG-2 trial (NCT06151574) will further assess Zongertinib in the first-line setting, providing critical data on its role relative to current standard-of-care therapies.

Conclusion
Zongertinib has emerged as a strong candidate in the evolving landscape of HER2-mutant NSCLC. With high response rates, durable outcomes, and a favorable safety profile, it may soon offer oncologists a powerful new tool for treating this difficult-to-manage patient population.

Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer. Heymach JV, Ruiter G, Ahn M-J, et al. for the Beamion LUNG-1 Investigators. Published April 28, 2025. DOI: 10.1056/NEJMoa2503704

Perioperative KEYTRUDA® Reshapes the Treatment Landscape for Resectable Locally Advanced HNSCC

RR

SUMMARY: The American Cancer Society estimates that 59,660 new cases of cancer involving the oral cavity and pharynx will be diagnosed in the US in 2025 and 12,770 will die of the disease. The head and neck region includes the oral cavity, oropharynx, hypopharynx and larynx. Squamous Cell Carcinoma (SCC) of the Head and Neck accounts for about 3-5% of all cancers in the United States. Common risk factors include tobacco and alcohol use and Human PapillomaVirus (HPV) infection. Even though tobacco has long been associated with head and neck cancer development, cannabis has similar carcinogens.

The Standard of Care for patients with Stage III–IVA Head and Neck Squamous Cell Carcinoma (HNSCC) has remained largely static for nearly 2 decades: surgery followed by risk-adapted adjuvant radiotherapy, with or without concurrent chemotherapy. Despite refinements in technique and supportive care, relapse rates remain high, particularly among patients with adverse pathological features such as extranodal extension and positive margins.

The treatment paradigm for Head and Neck cancer has been rapidly evolving with the recognition and better understanding of immune evasion and the role of immune checkpoints or gate keepers in suppressing antitumor immunity. Blocking the immune checkpoints unleashes the T cells, resulting in T cell proliferation, activation, and a therapeutic response. Checkpoint inhibitors administered in a neoadjuvant setting activates both the priming phase of immunity within tumor tissue, and the effector phase within the tumor microenvironment. It has been shown that neoadjuvant immunotherapy expands more T-cell clones than adjuvant treatment. Preclinical models have also demonstrated that both radiation therapy and Cisplatin chemotherapy increase the PD-L1 expression on the tumor, suggesting that combining radiotherapy with anti-PD-1 therapy could improve the outcomes.

Pembrolizumab (KEYTRUDA&reg;) is a fully humanized, Immunoglobulin G4, monoclonal antibody and checkpoint inhibitor, that binds to the PD-1 receptor and blocks its interaction with ligands PD-L1 and PD-L2, thereby undoing PD-1 pathway-mediated inhibition of the immune response and unleashing the tumor-specific effector T cells. Pembrolizumab has been shown to improve Overall Survival in patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

KEYNOTE-689, a landmark Phase 3 trial, has provided the most compelling evidence to date that perioperative immunotherapy, specifically Pembrolizumab, can significantly improve clinical outcomes for patients with resectable, locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC). This international, randomized, placebo-controlled study enrolled 714 patients (N=714) with newly diagnosed, resectable, Stage III–IVA HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx.

Patients were randomized 1:1 to receive:

  • Investigational arm (N=356):
    • 2 cycles of neoadjuvant Pembrolizumab (200 mg IV Q3W) starting about 3 weeks before surgery.
    • Standard-of-care surgery.
    • Up to 3 doses of Pembrolizumab administered concurrently with adjuvant chemoradiotherapy (depending on pathologic risk).
    • 12 additional adjuvant doses of Pembrolizumab Q3W (total treatment duration: about 1 year).
  • Control arm (N=358):
    • Identical treatment structure, substituting placebo for Pembrolizumab.

PD-L1 expression was assessed via Combined Positive Score (CPS), and stratification included CPS ≥1 and CPS ≥10 subgroups, recognizing the prognostic and potentially predictive value of PD-L1 expression. The Primary endpoint was Event-Free Survival (EFS), defined as time from randomization to disease progression, local/regional recurrence, distant metastasis, or death from any cause. Secondary endpoints included Overall Survival (OS) and Major Pathological Response.

The trial met its Primary endpoint of EFS. At median follow-up of 38.3 months, patients in the investigational arm had significantly improved EFS compared with the Standard of Care arm (median 51.8 months vs. 30.4 months; HR=0.73; P=0.0041). Patients who received Pembrolizumab who had a CPS score ≥10 derived the greatest benefit (median 59.7 months vs. 26.9 months; HR = 0.66; P=0.002) whereas the median EFS in the CPS ≥1 subgroup was 59.7 vs. 29.6 months (HR, 0.70; P = .0014).

Major pathological response defined as 90% or more tumor regression was also notably improved. Among all patients, the major pathological response rate was 9.4% with Pembrolizumab vs. 0% with Standard of Care (P < 0.00001). In the CPS ≥10 subgroup, the major pathological response rate reached 13.7%.

While the interim analysis did not demonstrate a statistically significant OS benefit, trends were favorable, particularly in the CPS ≥10 group (HR, 0.72; P =0.02). Further OS follow-up is ongoing.

Adverse events were consistent with known profiles of checkpoint inhibitors. Grade 3 or more  Treatment-Related Adverse Events (TRAEs) occurred in 44.6% of the Pembrolizumab group and 42.9% in the Standard of Care group. Immune-mediated adverse events were observed in 43.2% of the Pembrolizumab arm, with hypothyroidism being the most common (24.7%). Mortality attributable to treatment was slightly higher with Pembrolizumab (1.1% vs. 0.3%).

The researchers concluded that perioperative Pembrolizumab is now emerging as a new standard of care in the treatment of resectable locally advanced HNSCC. The findings from this study underscore the importance of harnessing the immune system both before and after surgery. Neoadjuvant administration may prime the immune response when tumor antigen burden is highest, while adjuvant therapy may help eliminate residual microscopic disease.

Neoadjuvant and adjuvant pembrolizumab plus standard of care in resectable locally advanced head and neck squamous cell carcinoma: phase 3 KEYNOTE-689 study. Uppaluri R, et al. Abstract CT001. Presented at: American Association for Cancer Research Annual Meeting; April 25-30, 2025; Chicago.

 

Prostate Cancer Screening with Polygenic Risk Score

RR

SUMMARY: Prostate cancer is the most common cancer in American men with the exclusion of skin cancer, and 1 in 8 men will be diagnosed with prostate cancer during their lifetime. It is estimated that in the United States, about 313,780 new cases of prostate cancer will be diagnosed in 2025 and 35,770 men will die of the disease

PSA is one of the most widely used prostate cancer biomarkers, and the widespread use of PSA testing in the recent years has resulted in a dramatic increase in the diagnosis and treatment of prostate cancer. PSA-based screening is widely debated due to false positives, overdiagnosis, and overtreatment.

The researchers in the present study hypothesized that Polygenic Risk Scores (PRS) based on aggregation of common genetic variants offer a promising way to stratify individual risk, independent of PSA or family history. Following completion of a pilot study, the BARCODE1 study was designed to prospectively test whether using a Polygenic Risk Score (PRS) could improve targeted screening effectiveness.

STUDY DESIGN:
BARCODE1 is a prospective, population-based, genetic risk-stratified screening study which included 6,393 men aged 55-69 yrs, with their Polygenic Risk Score calculated and recruited from 130 UK general practices. Germline DNA from saliva was used to calculate Polygenic Risk Score based on 130 known prostate cancer SNPs (Single Nucleotide Polymorphisms). Single Nucleotide Polymorphisms (SNPs “snips”) are variations in certain genes of a person’s DNA that can increase or decrease an individual’s risk of susceptibility to the disease. Men in the top 10% of the Polygenic Risk Score distribution (N=745) were invited for further screening with multiparametric MRI (mpMRI) and transperineal biopsy, regardless of PSA level.

KEY RESULTS:
MRI/biopsy was performed in 468 of these 745 men and 40% (N=187) were diagnosed with prostate cancer. Of the 187 participants, 103 men (55.1%) had clinically significant (Grade Group ≥2) cancer.

High-risk (Grade Group 3-5) cancer was found in 21.4% (N=40) of diagnosed men. These cancers typically qualify for radical therapy.

Current UK PSA thresholds (PSA >3.0 ng/mL) would have missed 71.8% of clinically significant cancers found through Polygenic Risk Score-based screening. Notably, 52% of all clinically significant cases had PSA <3.0 ng/mL, reinforcing the inadequacy of PSA-alone screening.

Estimated overdiagnosis (Grade Group 1 tumors) was 15.6–20.8%, comparable to, or lower than rates seen in PSA-based screening.

mpMRI-negative but Polygenic Risk Score-positive men still had a 6.4% clinically significant prostate cancer detection rate, underscoring Polygenic Risk Score value beyond imaging.

CONCLUSION:
Polygenic Risk Score-based screening detected more clinically significant prostate cancers than PSA or mpMRI alone. Combining Polygenic Risk Score with age and family history may help optimize risk-based screening strategies. One important limitation of this study is that participants were mostly educated men of European ancestry. These results may therefore not generalize to other ethnic groups or broader populations. Further research is needed to assess cost-effectiveness, utility across ancestries, and integration of genomics into national screening programs.

Polygenic Risk Score for Prostate Cancer Screening. McHugh JK, Bancroft EK, Saunders E, et al. for the BARCODE1 Steering Committee and Collaborators. N Engl J Med 2025;392:1406-1417

FDA Approves OPDIVO® Plus YERVOY® for Unresectable or Metastatic MSI-H/MMR Deficient Colorectal Cancer

RR

SUMMARY: The FDA on April 8, 2025, approved Nivolumab (OPDIVO®) with Ipilimumab (YERVOY®) for adult and pediatric patients 12 years of age and older with unresectable or metastatic MicroSatellite Instability-High (MSI-H) or MisMatch Repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent Nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following Fluoropyrimidine, Oxaliplatin, and Irinotecan.

Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society estimates that approximately 154,270 new cases of CRC will be diagnosed in the United States in 2025 and about 52,900 patients will die of the disease. The lifetime risk of developing CRC is about 1 in 23. The majority of CRC cases (about 75 %) are sporadic whereas the remaining 25 % of the patients have a family history of the disease. Only 5-6 % of patients with CRC with a family history background are due to inherited mutations in major CRC genes, while the rest are the result of accumulation of both genetic mutations and epigenetic modifications of several genes. Colorectal Cancer is a heterogeneous disease classified by its genetics, and even though the diagnosis of Colorectal Cancer in the US is dropping among people 65 years and older, the incidence has been rising in the younger age groups, with 12% of Colorectal Cancer cases diagnosed in people under age 50.

The DNA MisMatchRepair (MMR) system is responsible for molecular surveillance and works as an editing tool that identifies errors within the microsatellite regions of DNA and removes them. Defective MMR system leads to MSI (Micro Satellite Instability) and hypermutation, with the expression of tumor-specific neoantigens at the surface of cancer cells, triggering an enhanced antitumor immune response. MSI is therefore a hallmark of defective/deficient DNA MisMatchRepair (dMMR) system and occurs in 15% of all colorectal cancers. Defective MMR can be a sporadic or heritable event. Approximately 65% of the MSI high colon tumors are sporadic and when sporadic, the DNA MMR gene is MLH1. Defective MMR can manifest as a germline mutation occurring in MMR genes including MLH1, MSH2, MSH6 and PMS2. This produces Lynch Syndrome often called Hereditary Nonpolyposis Colorectal Carcinoma – HNPCC, an Autosomal Dominant disorder that is often associated with a high risk for Colorectal and Endometrial carcinoma, as well as several other malignancies including Ovary, Stomach, Small bowel, Hepatobiliary tract, Brain and Skin. MSI is a hallmark of Lynch Syndrome-associated cancers. MSI high tumors tend to have better outcomes and this has been attributed to the abundance of tumor infiltrating lymphocytes in these tumors from increase immunogenicity. These tumors therefore are susceptible to blockade with immune checkpoint inhibitors.

MSI testing is performed using a PCR or NGS based assay and MSI-High refers to instability at 2 or more of the 5 mononucleotide repeat markers and MSI-Low refers to instability at 1 of the 5 markers. Patients are considered Micro Satellite Stable (MSS) if no instability occurs. MSI-L and MSS are grouped together because MSI-L tumors are uncommon and behave similar to MSS tumors. Tumors considered MSI-H have deficiency of one or more of the DNA MMR genes. MMR gene deficiency can be detected by ImmunoHistoChemistry (IHC). NCCN Guidelines recommend MMR or MSI testing for all patients with a history of Colon or Rectal cancer. Unlike Colorectal and Endometrial cancer, where MSI-H/dMMR testing is routinely undertaken, the characterization of Lynch Syndrome across heterogeneous MSI-H/dMMR tumors is unknown.

Nivolumab is a fully human, immunoglobulin G4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, whereas Ipilimumab is a fully human immunoglobulin G1 monoclonal antibody that blocks Immune checkpoint protein/receptor CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4, also known as CD152). Blocking the Immune checkpoint proteins unleashes the T cells, resulting in T cell proliferation, activation and a therapeutic response.

The present FDA approval is based on CheckMate 8HW, which is an ongoing Phase III, multinational, open-label, randomized trial evaluating Nivolumab plus Ipilimumab as compared with Nivolumab alone or chemotherapy, in patients with MSI-H or dMMR metastatic CRC. In this study, patients with unresectable or mCRC and MSI-H/dMMR status by local testing who had received 0-1 prior line of therapy were randomly assigned in a 2:2:1 ratio to receive either Nivolumab monotherapy (N=353), Nivolumab plus Ipilimumab combination therapy (N=354), or the investigator’s choice of chemotherapy (mFOLFOX6 or FOLFIRI with or without Bevacizumab or Cetuximab (N=132). Patients who had previously received two or more prior lines of therapy for unresectable or metastatic disease were randomly assigned, in a 1:1 ratio, to receive Nivolumab plus Ipilimumab or Nivolumab alone. In the Nivolumab monotherapy arm, patients received Nivolumab 240 mg IV once every two weeks for six doses, followed by 480 mg IV every four weeks. In the Nivolumab plus Ipilimumab arm, patients were given Nivolumab 240 mg IV plus Ipilimumab 1mg/kg IV every three weeks for four doses, followed by Nivolumab 480 mg IV every four weeks. The median patient age was 64 years and tumor location was in the right colon in two thirds of the patients. Treatments continued until disease progression or unacceptable toxicity in all treatment groups or a maximum of 2 years. The dual Primary end points were Progression-Free Survival (PFS) as determined by Blinded Independent Central Review (BICR) comparing Nivolumab plus Ipilimumab to chemotherapy in the first-line therapy setting, and PFS comparing Nivolumab monotherapy to Nivolumab plus Ipilimumab across all lines of therapy, in patients with centrally confirmed MSI-H/dMMR metastatic CRC. At a median follow-up of 31.5 months the results from the prespecified interim analysis (the primary analysis) showed that the PFS outcomes were significantly better with Nivolumab plus Ipilimumab than with chemotherapy (HR=0.21; P<0.001).

The researchers herein reported the first results from the other dual Primary endpoint of PFS for Nivolumab plus Ipilimumab versus Nivolumab monotherapy across all lines of therapy in patients with centrally confirmed MSI-H/dMMR metastatic CRC. Of all the randomized patients 296 in the Nivolumab plus Ipilimumab group and 286 in the Nivolumab monotherapy group had centrally confirmed MSI-H/dMMR status. With a median follow-up of 47.0 months, Nivolumab plus Ipilimumab demonstrated clinically meaningful and statistically significant improvement in PFS by BICR versus Nivolumab monotherapy, with a median PFS Not Reached (NR) in the Nivolumab plus Ipilimumab group, compared to 39.3 months for those on Nivolumab monotherapy (HR=0.62; P= 0.0003). The PFS rates at 12, 24, and 36 months were higher in the Nivolumab plus Ipilimumab group at 76%, 71%, 68% versus 63%, 56%, 51% for Nivolumab monotherapy. The Objective Response Rate (ORR) was significantly higher with Nivolumab plus Ipilimumab at 71%, compared to 58% with Nivolumab alone (P=0.0011). No new safety concerns were identified.

It was concluded that the CheckMate 8HW study met its dual Primary endpoints, with Nivolumab plus Ipilimumab demonstrating a statistically significant and clinically meaningful improvement in PFS compared to Nivolumab monotherapy across all lines of therapy in MSI-H/dMMR metastatic CRC. Moreover, Nivolumab plus Ipilimumab was associated with higher ORR, confirming its potential as a new standard of care for patients with MSI-H/dMMR metastatic CRC. The CheckMate 8HW study is a pivotal contribution to the treatment landscape of MSI-H/dMMR metastatic Colorectal cancer, providing compelling evidence for the use of Nivolumab plus Ipilimumab in the first-line and beyond.

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Andre T, Elez E, Lenz H-J, et al. The Lancet. 2025; 405:383-395

Metabolic Syndrome and Breast Cancer Prognosis: A Comprehensive Meta-Analysis Highlights Urgent Need for Integrated Survivorship Strategies

RR

SUMMARY: Breast cancer is the most common cancer among women in the US and about 1 in 8 women (12%) will develop invasive breast cancer during their lifetime. It is estimated that in the US, approximately 316,950 new cases of female breast cancer will be diagnosed in 2025, and about 42,170 women will die of the disease, largely due to metastatic recurrence.

Background and Rationale: As oncologists continue to shift from a purely disease-focused model to one that embraces survivorship, a growing body of evidence suggests that metabolic syndrome may play a crucial, underappreciated role in determining long-term outcomes for women diagnosed with breast cancer.
Metabolic syndrome—characterized by the presence of at least three of the following risk factors: hypertension, hyperglycemia, central obesity, hypertriglyceridemia, and low HDL cholesterol—is known to elevate the risk for cardiovascular and chronic metabolic diseases. More recently, it has also been implicated in breast cancer incidence and prognosis, potentially through inflammatory, hormonal, and metabolic pathways.

Study Objective: A recent systematic review and meta-analysis sought to quantify the impact of metabolic syndrome on breast cancer-specific outcomes, including recurrence, mortality, and disease-free survival (DFS). The goal: to assess whether metabolic syndrome at the time of breast cancer diagnosis correlates with a poorer prognosis, independent of other risk factors.

Methodology, Study Population and Demographics: The investigators performed systematic literature searches in PubMed and Embase, using combinations of search terms like breast neoplasms, metabolic syndrome, and survival and From an initial pool of 1,019 studies, 17 high-quality studies were selected for meta-analysis and data were drawn from 42,135 breast cancer survivors. Seven studies, which included 9029 women, provided data on breast cancer recurrence, another 7 studies involving 31,008 women reported on breast cancer mortality, and 8 studies with 17,235 women provided data on Overall Survival (OS). These studies were conducted across North America, Europe, and Asia, the average age was 53.2 years and average follow-up time was 94.8 months. Metabolic syndrome was defined consistently across studies based on AHA criteria: presence of ≥3 of the following—waist circumference >35 inches (women), elevated triglycerides, reduced HDL-C, high fasting glucose, and elevated blood pressure.

Results: The analysis revealed statistically significant associations between metabolic syndrome and adverse breast cancer outcomes. Patients with metabolic syndrome had a 69% increased risk of recurrence, 83% increased risk of breast cancer-related death (Breast Cancer Specific Mortality) and 57% higher likelihood of experiencing an adverse event (recurrence, new malignancy, or death) impacting Disease-Free Survival. Subgroup analyses showed geographically consistent associations across North America, Europe, and Asia, reinforcing the global applicability of the findings.

Limitations:

  • Lack of consistent reporting on ER status, preventing stratified analysis by tumor subtype
  • Inability to isolate effects of individual metabolic components
  • Missing data on pharmacological treatments (e.g., statins, antidiabetics)
  • Residual confounding factors (e.g., socioeconomic status, lifestyle, genetics)
  • Predominantly observational designs, limiting causal inference

Clinical Implications: This study sheds light on an often-overlooked factor in breast cancer prognosis: metabolic health at diagnosis. With over 40,000 survivors included, the findings make a compelling case for integrating metabolic screening and intervention into breast cancer care pathways. Cardiovascular disease is the second leading cause of death among breast cancer survivors. Managing metabolic syndrome could address both cancer and cardiovascular risk.

Opportunities for Oncologists:

  • Early metabolic screening for BC patients at diagnosis and during follow-up
  • Interdisciplinary care involving endocrinologists, dietitians, and cardiologists
  • Lifestyle counseling as a standard element of survivorship care
  • Pharmacologic management using statins, antihypertensives, and antidiabetic agents with potential antitumor effects

Conclusion: Metabolic syndrome is more than a cardiovascular risk factor—it’s a cancer prognostic marker. This meta-analysis, the most comprehensive to date, makes it clear: women diagnosed with both breast cancer and metabolic syndrome face significantly worse outcomes. Clinical guidelines should evolve to include routine metabolic screening and targeted interventions for breast cancer survivors. Addressing metabolic health may be one of the most cost-effective ways to improve survival and quality of life in this growing population.

Metabolic syndrome is associated with breast cancer mortality: A systematic review and meta-analysis. Harborg S, Larsen HB, Elsgaard S, et al. J Intern Med. 2025;297:262-275.